MA global consultancy working on behalf of a well-known private equality firm is looking to purchase a majority share in a company active in producing pharmaceuticals and plasma derivatives for treating unusual and rare pathologies.
Aside from any agreements currently in place between the target company and relevant healthcare authorities, the buyer specifically requests high industrial quality and safety standards. The existence of a suitable technological research and innovation center would also be highly appreciated.
Any potential contact will be handled with the utmost professional discretion.